G

    Greenwich Lifesciences Inc (GLSI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.95
    -0.72 (-4.59%)

    Market Cap: $230.01M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(17/24)
    Avg Surprise
    -0.33%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.34
    Range$-0.37 - $-0.30
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.34+0.0%
    60d ago$-0.34+0.0%
    30d ago$-0.37-10.4%
    7d ago$-0.37-10.4%
    Current$-0.34
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.37
    Range$-0.47 - $-0.28
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.37---
    Sep 26EST
    		-$-0.34---
    Jun 26
    		$-0.27$-0.33+18.18%Beat+10.0%
    Mar 26
    		$-0.39$-0.32-21.88%Miss-56.0%
    Dec 25
    		$-0.58$-0.34-70.59%Miss+4.9%
    Sep 25
    		$-0.30$-0.36+16.67%Beat-50.0%
    Jun 25
    		$-0.30$-0.24-25.00%Miss-50.0%
    Mar 25
    		$-0.25$-0.24-4.17%Miss-31.6%
    Dec 24
    		$-0.61$-0.21-190.48%Miss-185.3%
    Sep 24
    		$-0.20$-0.21+4.76%Beat-5.3%
    Jun 24
    		$-0.20$-0.20+0.00%Beat-53.8%
    Mar 24
    		$-0.19$-0.20+5.00%Beat-11.8%
    Dec 23
    		$-0.21$-0.22+2.82%Beat+2.8%
    Sep 23
    		$-0.19$-0.22+13.64%Beat-5.6%
    Jun 23
    		$-0.13$-0.23+43.48%Beat-116.7%
    Mar 23
    		$-0.17$-0.23+26.09%Beat-13.3%
    Dec 22
    		$-0.22$-0.22+0.00%Beat-22.2%
    Sep 22
    		$-0.18$-0.19+5.26%Beat-157.1%
    Jun 22
    		$-0.06N/A+68.42%Beat+0.0%
    Mar 22
    		$-0.15$-0.19+21.05%Beat-200.0%
    Dec 21
    		$-0.18$-0.07-157.14%Miss-50.0%
    Sep 21
    		$-0.07$-0.06-16.67%Miss-133.3%
    Jun 21
    		$-0.06N/A+81.25%Beat-200.0%
    Mar 21
    		$-0.05N/A+84.38%Beat-150.0%
    Dec 20
    		$-0.12N/A+87.10%Beat+55.6%
    Sep 20
    		$-0.03$-0.03+0.00%Beat+97.4%
    Jun 20
    		$-0.02$0.00N/AMiss+99.8%
    Mar 20
    		$-0.02$0.00N/AMiss+97.3%
    Dec 19
    		$-0.27$0.00N/AMiss-
    Jun 19
    		$-1.15$0.00N/AMiss-
    Mar 19
    		$-12.83$0.00N/AMiss-
    Dec 18
    		$-0.73$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-9.71EV/EBITDA-21.23x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-986.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.54xQuick Ratio1.54x
    Trading Statistics
    Beta1.45Avg Volume134.96K
    52-Week High$34.1052-Week Low$7.78

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.03
    SMA 20$16.31
    SMA 50$17.27
    SMA 200$20.97
    EMA 10$16.71
    EMA 20$16.55
    EMA 50$17.67
    EMA 200$19.26

    MACD

    Line: 0.05Signal: -0.02Hist: 0.07

    ADX

    ADX: 18.3+DI: 18.1-DI: 26.6

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down8.0
    PSAR$19.53

    Bollinger Bands

    Upper Band$19.22
    Lower Band$13.40
    %B Position3573%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    42.6

    Momentum Oscillators

    Stoch %K40.2
    Stoch %D59.8
    Williams %R-87.0
    ROC (10d)-14.0%
    Momentum-2.43
    CCI (20d)-82.4
    MFI (14d)59.1

    Volatility Measures

    ATR (14d)$1.71(11.5%)
    StdDev (20d)1.46
    Hist Vol101.5%(High)

    Volume Flow

    VWAP$14.92
    OBV7.7M
    AD Line-11.7M
    CMF (20d)-0.072

    Volume Metrics

    Avg Vol (20d)135.5K
    Vol Ratio1.2x
    VWMA (20d)$16.21

    Pivot Points

    R3$23.01
    R2$20.98
    R1$18.32
    Pivot Point$16.29
    S1$13.63
    S2$11.60
    S3$8.94

    Advanced Oscillators

    TSI1.01
    Ultimate Osc50.9
    KST80.71

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$4.02M$5.73M$7.94M$4.17M$3.77M$2.77M$9.71M$2.73M$2.66M$2.54M$2.84M$2.50M
    R&D$3.56M$5.21M$7.59M$3.52M$3.42M$2.27M$8.69M$2.29M$2.31M$2.19M$2.33M$2.16M
    SG&A$462,931$518,190$355,194$653,066$352,838$497,602$1.02M$437,011$353,531$342,688$503,052$344,758
    Operating Income$-4,021,645$-5,725,754$-7,944,991$-4,174,642$-3,769,315$-2,768,750$-9,709,571$-2,729,051$-2,661,404$-2,537,201$-2,836,033$-2,502,925
    Interest Income$72,970$68,617$22,258$22,797$20,675$23,970$43,942$60,338$54,722$64,006$89,294$111,136
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-3,948,675$-5,657,137$-7,922,733$-4,151,845$-3,748,640$-2,744,780$-9,665,629$-2,668,713$-2,606,682$-2,473,195$-2,746,739$-2,391,789
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,948,675$-5,657,137$-7,922,733$-4,151,845$-3,748,640$-2,744,780$-9,665,629$-2,668,713$-2,606,682$-2,473,195$-2,746,739$-2,391,789
    EBITDA$-4,021,645$-5,725,754$-7,944,991$-4,174,642$-3,768,439$-2,767,847$-9,708,668$-2,728,148$-2,660,501$-2,536,298$-2,835,130$-2,502,022
    EBIT$-4,021,645$-5,725,754$-7,944,991$-4,174,642$-3,769,315$-2,768,750$-9,709,571$-2,729,051$-2,661,404$-2,537,201$-2,836,033$-2,502,925
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GLSI

    News

    Greenwich LifeSciences (NASDAQ:GLSI) Posts Quarterly Earnings Results

    Greenwich LifeSciences (NASDAQ:GLSI) announced its quarterly earnings, reporting a loss of $0.27 per share, which exceeded analyst expectations of a $0.33 loss. The company's stock traded around $15.55, significantly below its 12-month high, with a market capitalization of approximately $228 million. Despite mixed analyst ratings, CEO Snehal Patel recently increased his stake, and insiders collectively own over 51% of the company.

    MarketBeat•8/11/26•
    Neutral

    Greenwich LifeSciences 2Q 2026: Revenue $0 Net loss $(3.95M), EPS $(0.27) — 10-Q Summary

    Greenwich LifeSciences (GLSI) reported no product revenue for Q2 2026, consistent with the prior year. The company posted a net loss of $(3.95M), or $(0.27) per diluted share, a slight improvement in EPS compared to the $(0.28) loss in Q2 2025. Key activities include the ongoing Flamingo-01 Phase III trial for GLSI-100, clinical expansion with plans for up to 150 global sites, and preparation for future commercialization.

    TradingView•8/11/26•
    Neutral

    Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

    Greenwich LifeSciences (GLSI) has extended the lock-up period for shares owned by its directors, officers, and pre-IPO investors until January 31, 2027. This decision aims to support strategic and financing transactions, with CEO Snehal Patel highlighting increasing interest in their Phase III clinical trial, FLAMINGO-01, for preventing breast cancer recurrences. The company is actively pursuing partnerships and financial opportunities as the clinical trial progresses.

    GlobeNewswire•8/10/26•
    Bullish

    Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

    Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced an extension of the lock-up period for shares owned by its directors, officers, and pre-IPO investors until January 31, 2027. This decision aims to support strategic and financing transactions, particularly as the company progresses with its Phase III clinical trial, FLAMINGO-01, for GLSI-100, an immunotherapy to prevent breast cancer recurrences. The Board retains the flexibility to modify or terminate the lock-up at any time.

    The Manila Times•8/10/26•
    Somewhat-Bullish

    Greenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027

    Greenwich LifeSciences has extended the lock-up period for shares held by its directors, officers, and pre-IPO investors until January 31, 2027. This decision, announced by the Board of Directors, signifies confidence in the company's long-term strategy and ongoing Phase III clinical trial for GLSI-100, an immunotherapy to prevent breast cancer recurrences. After the lock-up, share sales will be subject to a leak-out plan, though the Board retains the flexibility to modify these terms.

    Quiver Quantitative•8/10/26•
    Somewhat-Bullish

    Frequently Asked Questions About GLSI

    Does GLSI pay dividends?
    Greenwich Lifesciences Inc (GLSI) does not currently pay a regular dividend.
    What is GLSI's market cap?
    Greenwich Lifesciences Inc (GLSI) has a market capitalization of $230.01M with a current stock price of $14.95.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In